Physician profile
Christopher M Perry
NPI 1184821167
$1,758.31
in general payments reported to CMS, 2019-2025
7 companies · $730 in 2025
The $730 reported for 2025 was more than what 94% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $187 · 2022: $361 · 2023: $14.77 · 2024: $466 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $830.92 | 2022-2025 | Fasenra, Andexxa |
| Abbvie INC. | $243.79 | 2024-2025 | |
| C. R. Bard, INC. & Subsidiaries | $186.67 | 2020 | |
| Gilead Sciences, INC. | $128.30 | 2022-2023 | |
| Glaxosmithkline, LLC. | $125.00 | 2025 | Penmenvy |
| Novo Nordisk INC | $121.85 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $121.78 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.